Principles behind SLE treatment with N-acetylcysteine-Immunometabolism-CSCIED科技核心评价数据库-手机版

Principles behind SLE treatment with N-acetylcysteine

Principles behind SLE treatment with N-acetylcysteine

ES评分 0 浏览量：1063 下载量：0

DOI	10.1097/IN9.0000000000000010
刊名	Immunometabolism IJ
年，卷(期)	2022, 4(4)
作者	Nasr, Sandy; Perl, Andras,
作者单位	[Nasr, Sandy; Perl, Andras] SUNY Syracuse, Coll Med, Dept Med, Syracuse, NY 13244 USA
摘要	Systemic lupus erythematous (SLE) is a multisystem chronic autoimmune disease in which disrupted molecular pathways lead to multiple clinical manifestations. Currently approved treatments include hydroxychloroquine, some immunosuppressive medications, and some biologics. They all come with a range of side effects. N-acetylcysteine (NAC) is an antioxidant that has shown potential benefits in SLE patients without having major side effects. The following review highlights the molecular mechanisms behind the therapeutic effect of NAC in SLE patients. A higher-than normal mitochondrial transmembrane potential or mitochondrial hyperpolarization (MHP) was found in lymphocytes from SLE patients. MHP is attributed the blocked electron transport, and it is associated with the depletion of ATP and glutathione and the accumulation of oxidative stress-generating mitochondria due to diminished mitophagy. Comprehensive metabolome analyses identified the accumulation of kynurenine as the most predictive metabolic biomarker of lupus over matched healthy subjects. Cysteine is the rate-limiting constituent in the production of reduced glutathione, and it can be replaced by its precursor NAC. Kynurenine accumulation has been reversed by treatment with NAC but not placebo in the setting of a double-blind placebo-controlled clinical trial of 3-month duration. Mitochondrial oxidative stress and its responsiveness to NAC have been linked to systemic inflammation, gut microbiome changes, and organ damage in lupus-prone mice. Given the unique safety of NAC and chronicity of SLE, the clinical trial of longer duration is being pursued.
Abstract	Systemic lupus erythematous (SLE) is a multisystem chronic autoimmune disease in which disrupted molecular pathways lead to multiple clinical manifestations. Currently approved treatments include hydroxychloroquine, some immunosuppressive medications, and some biologics. They all come with a range of side effects. N-acetylcysteine (NAC) is an antioxidant that has shown potential benefits in SLE patients without having major side effects. The following review highlights the molecular mechanisms behind the therapeutic effect of NAC in SLE patients. A higher-than normal mitochondrial transmembrane potential or mitochondrial hyperpolarization (MHP) was found in lymphocytes from SLE patients. MHP is attributed the blocked electron transport, and it is associated with the depletion of ATP and glutathione and the accumulation of oxidative stress-generating mitochondria due to diminished mitophagy. Comprehensive metabolome analyses identified the accumulation of kynurenine as the most predictive metabolic biomarker of lupus over matched healthy subjects. Cysteine is the rate-limiting constituent in the production of reduced glutathione, and it can be replaced by its precursor NAC. Kynurenine accumulation has been reversed by treatment with NAC but not placebo in the setting of a double-blind placebo-controlled clinical trial of 3-month duration. Mitochondrial oxidative stress and its responsiveness to NAC have been linked to systemic inflammation, gut microbiome changes, and organ damage in lupus-prone mice. Given the unique safety of NAC and chronicity of SLE, the clinical trial of longer duration is being pursued.
关键词	systemic lupus erythematosus; N-acetylcysteine; mechanistic target of rapamycin; mitochondrial hyperpolarization
KeyWord	systemic lupus erythematosus; N-acetylcysteine; mechanistic target of rapamycin; mitochondrial hyperpolarization
基金项目
页码	1-5

参考文献
相关文献

[1]. Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1–13. doi: 10.1016/j.jaut.2018.11.001.

[2]. Perl A. Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment. Autoimmunity. 2010;43:32–47. doi: 10.3109/08916930903374774.

[3]. Wallace DJ. The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol. 2015;11:616–20. doi: 10.1038/nrrheum.2015.86.

[4]. Tsokos GC, Lo MS, Reis PC, et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716–30. doi: 10.1038/nrrheum.2016.186.

[5]. Tipton CM, Fucile CF, Darce J, et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol. 2015;16:755–65. doi: 10.1038/ni.3175.

[6]. Gergely PJ, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002;46:175–90.

[7]. Banki K, Hutter E, Gonchoroff N, et al. Elevation of mitochondrial transmembrane potential and reactive oxygen intermediate levels are early events and occur independently from activation of caspases in Fas signaling. J Immunol. 1999;162:1466–79.

[8]. Chen PM, Katsuyama E, Satyam A, et al. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Sci Adv. 2022;8:eabo4271. doi: 10.1126/sciadv.abo4271.

[9]. Lai Z-W, Hanczko R, Bonilla E, et al. N-acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. Arthritis Rheum. 2012;64:2937–46. doi: 10.1002/art.34502.

[10]. Perl A. Mechanistic target of rapamycin pathway activation in rheumatic diseases. Nat Rev Rheumatol. 2016;12:169–82. doi: 10.1038/nrrheum.2015.172.

[11]. Mao Z, Tan Y, Tao J, et al. Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis. Rheumatology. 2022;61:3830–40. doi: 10.1093/rheumatology/keac037.

[12]. Oaks Z, Winans T, Caza T, et al. Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice. Arthritis Rheumatol. 2016;68:2728–39. doi: 10.1002/art.39791.

[13]. Stathopoulou C, Nikoleri D, Bertsias G. Immunometabolism: an overview and therapeutic prospects in autoimmune diseases. Immunotherapy. 2019;11:813–29. doi: 10.2217/imt-2019-0002.

[14]. Mokhtari V, Afsharian P, Shahhoseini M, et al. A review on various uses of N-Acetyl cysteine. Cell J. 2017;19:11–17. doi: 10.22074/cellj.2016.4872.

[15]. Suwannaroj S, Lagoo A, Keisler D, et al. Antioxidants suppress mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus. 2001;10:258–65. doi:10.1191/096120301680416940.

[16]. Shi D, Li X, Chen H, et al. High level of reactive oxygen species impaired mesenchymal stem cell migration via overpolymerization of F-actin cytoskeleton in systemic lupus erythematosus. Pathol Biol. 2014;62:382–90. doi: 10.1016/j.patbio.2014.07.009.

[17]. Wang H, Wang G, Liang Y, et al. Redox regulation of hepatic NLRP3 inflammasome activation and immune dysregulation in trichloroethene-mediated autoimmunity. Free Radic Biol Med. 2019;143:223–31. doi: 10.1016/j.freeradbiomed.2019.08.014.

[18]. Wang H, Wang G, Banerjee N, et al. Aberrant gut microbiome contributes to intestinal oxidative stress, barrier dysfunction, inflammation and systemic autoimmune responses in MRL/lpr mice. Front Immunol. 2021;12:651191. doi: 10.3389/fimmu.2021.651191.

[19]. Perl A, Hanczko R, Lai Z-W, et al. Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics. 2015;11:1157–74. doi: 10.1007/s11306-015-0772-0.

[20]. Kudaravalli J. Improvement in endothelial dysfunction in patients with systemic lupus erythematosus with N-acetylcysteine and atorvastatin. Ind J Pharmacol. 2011;43:311–15. doi: 10.4103/0253-7613.81511.

[21]. Garcia RJ, Francis L, Dawood M, et al. Attention deficit and hyperactivity disorder scores are elevated and respond to NAC treatment in patients with SLE. Arthritis Rheum. 2013;65:1313–18. doi: 10.1002/art.37893.

[22]. Doherty E, Oaks Z, Perl A. Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. Antioxid Redox Signal. 2014;21:56–65. doi: 10.1089/ars.2013.5702.

[23]. Berod L, Friedrich C, Nandan A, et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. 2014;20:1327–33. doi: 10.1038/nm.3704.

[24]. Warner LM, Adams LM, Sehgal SN. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 1994;37:289–97. doi: 10.1002/art.1780370219.

[25]. Caza TN, Fernandez D, Talaber G, et al. HRES-1/RAB4-mediated depletion of DRP1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann Rheum Dis. 2014;73:1887–97. doi: 10.1136/annrheumdis-2013-203794.

[26]. Rhodes K, Braakhuis A. Performance and side effects of supplementation with N-acetylcysteine: a systematic review and meta-analysis. Sports Med. 2017;47:1619–36. doi: 10.1007/s40279-017-0677-3.

[27]. Pedre B, Barayeu U, Ezerina D, et al. The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species. Pharmacol Ther. 2021;228:107916.

[28]. Paul M, Thushara RM, Jagadish S, et al. Novel sila-amide derivatives of N-acetylcysteine protects platelets from oxidative stress-induced apoptosis. J Thromb Thrombolysis. 2017;43:209–16. doi: 10.1007/s11239-016-1450-4.

[29]. Schwalfenberg GK. N-Acetylcysteine: a review of clinical usefulness (an old drug with new tricks). J Nutr Metab. 2021;2021:9949453. doi: 10.1155/2021/9949453.

[30]. Dos Santos TM, Graciliano NG, Moura FA, et al. N-Acetylcysteine (NAC): impacts on human health. Antioxidants. 2021;10:967. doi: 10.3390/antiox10060967.

[31]. Kumar P, Liu C, Hsu JW, et al. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial. Clin Transl Med. 2021;11:e372. doi: 10.1002/ctm2.372.

[32]. Lai Z, Kelly R, Winans T, et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet. 2018;391:1186–96. doi: 10.1016/S0140-6736(18)30485-9.

[33]. Piranavan P, Bhamra M, Perl A. Metabolic targets for treatment of autoimmune diseases. Immunometabolism. 2020;2:e200012. doi: 10.20900/immunometab20200012.

[34]. Mannick JB, Morris M, Hockey HU, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 2018;10:eaaq1564.

引用本文

Nasr, Sandy; Perl, Andras. Principles behind SLE treatment with N-acetylcysteine [J]. Immunometabolism. 2022; 4; (4). 1 - 5.

文献评论

相关学者

相关机构